<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ketoconazole</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01026</strong>&#160; (APRD00401)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Broad spectrum antifungal agent used for long periods at high doses, especially in immunosuppressed patients. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01026/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01026/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01026.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01026.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01026.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01026.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01026.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01026">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Ketoconazol</td><td>Spanish</td><td>INN</td></tr><tr><td>Ketoconazole</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN, BAN, USAN, JAN</td></tr><tr><td>Ketoconazolum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Extina</td><td>Stiefel</td></tr><tr><td>Fungarest</td><td>Janssen-Cilag</td></tr><tr><td>Fungoral</td><td>Johnson &amp; Johnson</td></tr><tr><td>Ketodan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ketoderm</td><td>Hessel</td></tr><tr><td>Ketoisdin</td><td>Isdin</td></tr><tr><td>Ketozole</td><td>Ranbaxy</td></tr><tr><td>Nizoral</td><td>Ortho-McNeil</td></tr><tr><td>Nizoral Cream</td><td>Ortho-McNeil</td></tr><tr><td>Nizoral Shampoo</td><td>Ortho-McNeil</td></tr><tr><td>Orifungal</td><td>Janssen</td></tr><tr><td>Orifungal M</td><td>Janssen</td></tr><tr><td>Panfungol</td><td>Esteve</td></tr><tr><td>Xolegel</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antifungal-agents">Antifungal Agents</a></li>
<li><a href="/mesh/14-alpha-demethylase-inhibitors">14-alpha Demethylase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>65277-42-1</td></tr><tr><th>Weight</th><td>Average: 531.431<br>Monoisotopic: 530.148760818</td></tr><tr><th>Chemical Formula</th><td>C<sub>26</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>XMAYWYJOQHXEEK-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C26H28Cl2N4O4/c1-19(33)31-10-12-32(13-11-31)21-3-5-22(6-4-21)34-15-23-16-35-26(36-23,17-30-9-8-29-18-30)24-7-2-20(27)14-25(24)28/h2-9,14,18,23H,10-13,15-17H2,1H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-[4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Piperazines</td></tr><tr><th>Subclass</th><td>Phenylpiperazines</td></tr><tr><th>Direct parent</th><td>Phenylpiperazines</td></tr><tr><th>Alternative parents</th><td>Dichlorobenzenes; Phenol Ethers; Alkyl Aryl Ethers; Aryl Chlorides; Diazinanes; N-substituted Imidazoles; Tertiary Carboxylic Acid Amides; 1,3-Dioxolanes; Tertiary Amines; Carboxylic Acids; Dialkyl Ethers; Polyamines; Acetals; Enolates; Organochlorides</td></tr><tr><th>Substituents</th><td>1,3-dichlorobenzene; phenol ether; chlorobenzene; alkyl aryl ether; aryl chloride; aryl halide; benzene; n-substituted imidazole; 1,4-diazinane; azole; imidazole; tertiary carboxylic acid amide; meta-dioxolane; tertiary amine; carboxamide group; ether; acetal; dialkyl ether; enolate; polyamine; carboxylic acid derivative; carboxylic acid; amine; organonitrogen compound; organohalogen; organochloride</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.</td></tr><tr><th>Pharmacodynamics</th><td>Ketoconazole, like clotrimazole, fluconazole, itraconazole, and miconazole, is an imidazole antifungal agent.</td></tr><tr><th>Mechanism of action</th><td>Ketoconazole interacts with 14-&#945; demethylase, a cytochrome P-450 enzyme necessary for the conversion of lanosterol to ergosterol. This results in inhibition of ergosterol synthesis and increased fungal cellular permeability. Other mechanisms may involve the inhibition of endogenous respiration, interaction with membrane phospholipids, inhibition of yeast transformation to mycelial forms, inhibition of purine uptake, and impairment of triglyceride and/or phospholipid biosynthesis. Ketoconazole can also inhibit the synthesis of thromboxane and sterols such as aldosterone, cortisol, and testosterone.</td></tr><tr><th>Absorption</th><td>Moderate</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>99% (in vitro, plasma protein binding)</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>2 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Hepatotoxicity, LD<sub>50</sub>=86 mg/kg (orally in rat)</td></tr><tr><th>Affected organisms</th><td><ul><li>Fungi</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9156</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.6704</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8866</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7293</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8389</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8388</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5644</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9115</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7409</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9106</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.8949</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8931</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8994</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.796</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.9386</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7003
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8836
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.4739 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9258
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8403
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Stiefel laboratories inc</li>
<li>Altana inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Taro pharmaceuticals usa inc</li>
<li>Janssen pharmaceutica products lp</li>
<li>Perrigo new york inc</li>
<li>Tolmar inc</li>
<li>Ortho mcneil janssen pharmaceuticals inc</li>
<li>Mcneil consumer healthcare</li>
<li>Aaipharma llc</li>
<li>Apotex inc</li>
<li>Mutual pharmacal co</li>
<li>Mylan pharmaceuticals inc</li>
<li>Pliva inc</li>
<li>Taro pharmaceutical industries ltd</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.apicalrx.com">Apical Pharmaceutical Corporation</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.davapharma.com">DAVA Pharmaceuticals</a></li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li><a href="http://www.dptlabs.com">DPT Laboratories Ltd.</a></li>
<li><a href="http://www.fougera.com">E. Fougera and Co.</a></li>
<li><a href="http://hjharkinscompanyinc.com">H.J. Harkins Co. Inc.</a></li>
<li><a href="http://www.janssen-ortho.com">Janssen-Ortho Inc.</a></li>
<li><a href="http://www.jsjpharm.com">JSJ Pharmaceuticals Inc.</a></li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li>McNeil Laboratories</li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Mutual Pharmaceutical Co.</li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Novopharm Ltd.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.nycomed.com">Nycomed Inc.</a></li>
<li><a href="http://www.ortho-mcneil.com">Ortho Mcneil Janssen Pharmaceutical Inc.</a></li>
<li><a href="http://www.ortho-mcneil.com">Ortho-McNeil-Janssen Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li><a href="http://www.patheon.com">Patheon Inc.</a></li>
<li><a href="http://www.patriotpharmaceuticals.com">Patriot Pharmaceuticals</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.perrigo.com">Perrigo Co.</a></li>
<li><a href="http://www.pharmapacllc.com">Pharma Pac LLC</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.pliva.com">Pliva Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li><a href="http://www.prescript.net">Prescript Pharmaceuticals</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.stiefel.com">Stiefel Labs</a></li>
<li><a href="http://www.tarousa.com">Taro Pharmaceuticals USA</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.tolmar.com">Tolmar Inc.</a></li>
<li>Torpharm Inc.</li>
<li>Tya Pharmaceuticals</li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Cream</td><td>Topical</td><td></td></tr><tr><td>Shampoo</td><td>Topical</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB05812">Abiraterone</a></td><td>Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Ketoconazole may increase the anticoagulant effect of acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00802">Alfentanil</a></td><td>Ketoconazole may increase the effect and toxicity of alfentanil.</td></tr><tr><td><a href="/drugs/DB00346">Alfuzosin</a></td><td>The antifungal increases the effect of alfuzosin</td></tr><tr><td><a href="/drugs/DB00918">Almotriptan</a></td><td>This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan</td></tr><tr><td><a href="/drugs/DB00404">Alprazolam</a></td><td>Ketoconazole may increase the effect of the benzodiazepine, alprazolam.</td></tr><tr><td><a href="/drugs/DB01370">Aluminium</a></td><td>Aluminum-containing antacids may decrease the effect of ketoconazole.</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of amitriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amitriptyline if ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Ketoconazole may increase the anticoagulant effect of anisindione.</td></tr><tr><td><a href="/drugs/DB06605">Apixaban</a></td><td>Avoid combination. Otherwise, ketoconazole will likely increase apixaban serum concentration.</td></tr><tr><td><a href="/drugs/DB00673">Aprepitant</a></td><td>This CYP3A4 inhibitor increases the effect and toxicity of aprepitant</td></tr><tr><td><a href="/drugs/DB01238">Aripiprazole</a></td><td>Ketoconazole may increase the effect of aripiprazole.</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Concurrent oral administration of ketoconazole, a potent CYP3A4 inhibitor, with a single dose of Coartem Tablets resulted in a moderate increase in exposure to artemether, DHA, and lumefantrine in a study of 15 healthy subjects.</td></tr><tr><td><a href="/drugs/DB00637">Astemizole</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB06237">Avanafil</a></td><td>Co-administration with the strong CYP3A4 inhibitor ketoconazole resulted in an approximate 13-fold increase in AUC0-inf and 3.1-fold increase in Cmax. </td></tr><tr><td><a href="/drugs/DB08903">Bedaquiline</a></td><td>Strong CYP3A4 inhibitors may increase exposure of bedaquiline. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00559">Bosentan</a></td><td>Ketoconazole may increase the effect and toxicity of bosentan.</td></tr><tr><td><a href="/drugs/DB06616">Bosutinib</a></td><td>Strong CYP3A4 inhibitors may increase levels of bosutinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01558">Bromazepam</a></td><td>Ketoconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01222">Budesonide</a></td><td>Ketoconazole may increase levels/effect of budesonide.</td></tr><tr><td><a href="/drugs/DB06772">Cabazitaxel</a></td><td>Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01373">Calcium</a></td><td>Calcium-containing antacids may decrease the absorption of ketoconazole.</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Ketoconazole may increase the effect of carbamazepine.</td></tr><tr><td><a href="/drugs/DB00439">Cerivastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00475">Chlordiazepoxide</a></td><td>Ketoconazole may increase the effect of the benzodiazepine, chlordiazepoxide.</td></tr><tr><td><a href="/drugs/DB01410">Ciclesonide</a></td><td>Increased effects/toxicity of ciclesonide</td></tr><tr><td><a href="/drugs/DB01166">Cilostazol</a></td><td>Ketoconazole may increase the effect of cilostazol.</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>The H2-receptor antagonist, cimetidine, may decrease the absorption of ketoconazole.</td></tr><tr><td><a href="/drugs/DB01012">Cinacalcet</a></td><td>Ketoconazole may increase the effect and toxicity of cinacalcet.</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00349">Clobazam</a></td><td>Clobazam may increase levels by affecting CYP2C19 metabolism. Interaction is significant so monitor closely. Dose adjustment may be necessary. </td></tr><tr><td><a href="/drugs/DB01068">Clonazepam</a></td><td>Ketoconazole may increase the effect of the benzodiazepine, clonazepam.</td></tr><tr><td><a href="/drugs/DB00628">Clorazepate</a></td><td>Ketoconazole may increase the effect of the benzodiazepine, clorazepate.</td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated. </td></tr><tr><td><a href="/drugs/DB08865">Crizotinib</a></td><td>Strong CYP3A4 inhibitors may increase levels of crizotinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Ketoconazole may increase the effect of cyclosporine.</td></tr><tr><td><a href="/drugs/DB06695">Dabigatran etexilate</a></td><td>Coadministration with a strong p-glycoprotein inhibitor may increase the level or effect of dabigatran. Monitor closely for adverse effects. </td></tr><tr><td><a href="/drugs/DB08912">Dabrafenib</a></td><td>Strong CYP3A4 inhibitors may increase levels of dabrafenib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01219">Dantrolene</a></td><td>Ketoconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if ketoconazole is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00496">Darifenacin</a></td><td>This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism</td></tr><tr><td><a href="/drugs/DB00829">Diazepam</a></td><td>Ketoconazole may increase the effect of the benzodiazepine, diazepam.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Ketoconazole may increase the anticoagulant effect of dicumarol.</td></tr><tr><td><a href="/drugs/DB00320">Dihydroergotamine</a></td><td>Possible ergotism and severe ischemia with this combination</td></tr><tr><td><a href="/drugs/DB01248">Docetaxel</a></td><td>Ketoconazole may increase the serum levels and toxicity of docetaxel.</td></tr><tr><td><a href="/drugs/DB00204">Dofetilide</a></td><td>This strong CYP3A4 inhibitor increases the effect and toxicity of dofetilide</td></tr><tr><td><a href="/drugs/DB04855">Dronedarone</a></td><td>Ketoconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use. </td></tr><tr><td><a href="/drugs/DB00216">Eletriptan</a></td><td>This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan</td></tr><tr><td><a href="/drugs/DB00700">Eplerenone</a></td><td>Ketoconazole, a CYP3A4 inhibitor, may increase the effect and toxicity of eplerenone.</td></tr><tr><td><a href="/drugs/DB00696">Ergotamine</a></td><td>Possible ergotism and severe ischemia with this combination.</td></tr><tr><td><a href="/drugs/DB00530">Erlotinib</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of erlotinib</td></tr><tr><td><a href="/drugs/DB00736">Esomeprazole</a></td><td>The proton pump inhibitor, esomeprazole, may decrease the absorption of ketoconazole.</td></tr><tr><td><a href="/drugs/DB01215">Estazolam</a></td><td>Ketoconazole may increase the effect of the benzodiazepine, estazolam.</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Etravirine, when used concomitantly with Ketoconazole (and other azole derivatives), may experience an increase in serum concentration.

Ketoconazole (and other azole derivatives), when used concomitantly with etravirine, may experience a decrease in serum concentration.

It is recommended to monitor etravirine therapy for toxicity. </td></tr><tr><td><a href="/drugs/DB01590">Everolimus</a></td><td>Ketoconazole may increase everolimus levels/toxicity.</td></tr><tr><td><a href="/drugs/DB00927">Famotidine</a></td><td>The H2-receptor antagonist, famotidine, may decrease the absorption of ketoconazole.</td></tr><tr><td><a href="/drugs/DB00813">Fentanyl</a></td><td>Ketoconazole may increase levels/toxicity of fentanyl.</td></tr><tr><td><a href="/drugs/DB06702">Fesoterodine</a></td><td>Ketoconazole is a potent CYP3A4 inhibitor thus reducing clearance. Avoid concomitant use with fesoterodine. </td></tr><tr><td><a href="/drugs/DB08868">Fingolimod</a></td><td>Exposure is increased by 70% during concomitant use with systemic ketoconazole, and risk of adverse reactions is greater.</td></tr><tr><td><a href="/drugs/DB00690">Flurazepam</a></td><td>Ketoconazole may increase the effect of the benzodiazepine, flurazepam.</td></tr><tr><td><a href="/drugs/DB08906">Fluticasone furoate</a></td><td>Strong CYP3A4 inhibitors may increase levels of fluticasone furoate. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00674">Galantamine</a></td><td>Ketoconazole increases the effect and toxicity of galantamine</td></tr><tr><td><a href="/drugs/DB00317">Gefitinib</a></td><td>This CYP3A4 inhibitor increases levels/toxicity of gefitinib</td></tr><tr><td><a href="/drugs/DB00222">Glimepiride</a></td><td>Ketoconazole increases the effect of rosiglitazone</td></tr><tr><td><a href="/drugs/DB00801">Halazepam</a></td><td>Ketoconazole may increase the effect of the benzodiazepine, halazepam.</td></tr><tr><td><a href="/drugs/DB00502">Haloperidol</a></td><td>Ketoconazole may increase the effect and toxicity of haloperidol.</td></tr><tr><td><a href="/drugs/DB04946">Iloperidone</a></td><td>Ketoconazole is a strong CYP3A4 inhibitor that increases serum concentration of iloperidone and likelihood of observing adverse effects such as QT prolongation. Reduce dose of iloperidone by 50% </td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Ketoconazole may increase the levels of imatinib.</td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of imipramine by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of imipramine if ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB05039">Indacaterol</a></td><td>Strong CYP3A4 inhibitors increase levels of indacaterol. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Indinavir may increase the serum concentration of ketoconazole. Ketoconazole may increase the serum concentration of indinavir. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if either agent is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00762">Irinotecan</a></td><td>Ketoconazole increases the effect and toxicity of irinotecan</td></tr><tr><td><a href="/drugs/DB00951">Isoniazid</a></td><td>Isoniazid decreases the effect of ketoconazole</td></tr><tr><td><a href="/drugs/DB08820">Ivacaftor</a></td><td>Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00448">Lansoprazole</a></td><td>The proton pump inhibitor, lansoprazole, may decrease the absorption of ketoconazole.</td></tr><tr><td><a href="/drugs/DB08918">Levomilnacipran</a></td><td>Strong CYP3A4 inhibitors may increase exposure levomilnacipran. </td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB08815">Lurasidone</a></td><td>Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated. </td></tr><tr><td><a href="/drugs/DB01377">Magnesium oxide</a></td><td>The antacid, magnesium oxide, may decrease the effect of ketoconazole by decreasing its absorption. </td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB00959">Methylprednisolone</a></td><td>The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone.</td></tr><tr><td><a href="/drugs/DB00683">Midazolam</a></td><td>Ketoconazole may increase the effect of the benzodiazepine, midazolam.</td></tr><tr><td><a href="/drugs/DB08893">Mirabegron</a></td><td>Concomitant therapy with p-glycoprotein and strong CYP3A4 inhibitors may increase levels of mirabegron. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00238">Nevirapine</a></td><td>Nevirapine, a strong CYP3A4 inducer, may decrease the serum concentration of ketoconazole by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of ketoconazole if nevirapine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00585">Nizatidine</a></td><td>The H2-receptor antagonist, nizatidine, may decrease the absorption of ketoconazole.</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>Ketoconazole, a moderate CYP2D6 inhibitor,  may increase the serum concentration of nortriptyline by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nortriptyline if ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00338">Omeprazole</a></td><td>The proton pump inhibitor, omeprazole, may decrease the absorption of ketoconazole.</td></tr><tr><td><a href="/drugs/DB04938">Ospemifene</a></td><td>Ketoconazole, a strong CYP3A4 inhibitor increases the systemic exposure of ospemifene by 1.4-fold. Administration of ketoconazole chronically with ospemifene may increase the risk of OSPHENA-related adverse reactions. </td></tr><tr><td><a href="/drugs/DB00213">Pantoprazole</a></td><td>The proton pump inhibitor, pantoprazole, may decrease the absorption of ketoconazole.</td></tr><tr><td><a href="/drugs/DB06589">Pazopanib</a></td><td>Ketoconazole is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib by 120% in healthy subjects. </td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01132">Pioglitazone</a></td><td>Ketoconazole increases the effect of pioglitazone</td></tr><tr><td><a href="/drugs/DB08910">Pomalidomide</a></td><td>Strong CYP3A4 inhibitors may increase levels of pomalidomide. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB08901">Ponatinib</a></td><td>Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB06209">Prasugrel</a></td><td>Ketoconazole is a potent inhibitor of CYP3A4 which decreases the Cmax of prasugrel due to a reduction of prasugrel bioactivation. However, there was no reduction of inhibition of platelet aggregation. </td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisolone.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisone.</td></tr><tr><td><a href="/drugs/DB01589">Quazepam</a></td><td>Ketoconazole may increase the effect of the benzodiazepine, quazepam.</td></tr><tr><td><a href="/drugs/DB01224">Quetiapine</a></td><td>Ketoconazole may increase the therapeutic and adverse effects of quetiapine.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Ketoconazole may increase the effect and toxicity of quinidine.</td></tr><tr><td><a href="/drugs/DB01346">Quinidine barbiturate</a></td><td>Ketoconazole may increase the effect and toxicity of quinidine barbiturate.</td></tr><tr><td><a href="/drugs/DB01129">Rabeprazole</a></td><td>The proton pump inhibitor, rabeprazole, may decrease the absorption of ketoconazole.</td></tr><tr><td><a href="/drugs/DB00980">Ramelteon</a></td><td>Ketoconazole may increase the serum levels and toxicity of ramelteon.</td></tr><tr><td><a href="/drugs/DB00863">Ranitidine</a></td><td>The H2-receptor antagonist, ranitidine, may decrease the absorption of ketoconazole.</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Increased levels of ranolazine - risk of toxicity</td></tr><tr><td><a href="/drugs/DB08896">Regorafenib</a></td><td>Strong CYP3A4 inhibitors may increase levels of regorafenib. </td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the effect of ketoconazole.</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ketoconazole may increase the effect and toxicity of ritonavir.</td></tr><tr><td><a href="/drugs/DB06228">Rivaroxaban</a></td><td>Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated.</td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Increases roflumilast levels. </td></tr><tr><td><a href="/drugs/DB00412">Rosiglitazone</a></td><td>Ketoconazole increases the effect of rosiglitazone</td></tr><tr><td><a href="/drugs/DB08877">Ruxolitinib</a></td><td>Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>Ketoconazole may increase the effect and toxicity of saquinavir.</td></tr><tr><td><a href="/drugs/DB06335">Saxagliptin</a></td><td>Ketoconazole is a strong inhibitor of CYP3A4/5 which increases exposure of saxagliptin. The exposure of the active metabolite, 5-hydroxy saxagliptin, also decreases. Decrease dose of saxagliptin to 2.5 mg per day. </td></tr><tr><td><a href="/drugs/DB01105">Sibutramine</a></td><td>Ketoconazole increases the levels and toxicity of sibutramine</td></tr><tr><td><a href="/drugs/DB00203">Sildenafil</a></td><td>Ketoconazole may increase the effect and toxicity of sildenafil.</td></tr><tr><td><a href="/drugs/DB06207">Silodosin</a></td><td>Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects </td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00877">Sirolimus</a></td><td>Ketoconazole may increase the effect and toxicity of sirolimus.</td></tr><tr><td><a href="/drugs/DB01591">Solifenacin</a></td><td>This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism</td></tr><tr><td><a href="/drugs/DB00364">Sucralfate</a></td><td>Sucralfate may decrease the absorption of ketoconazole.</td></tr><tr><td><a href="/drugs/DB01268">Sunitinib</a></td><td>Possible increase in sunitinib levels</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by strong CYP1A2 inhibitors such as Ketoconazole. Consider modifying therapy to avoid Tacrine toxicity. Monitor the efficacy and toxicity of Tacrine if Ketoconazole is initiated, discontinued or if the dose is changed.</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>The antifungal, Ketoconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Ketoconzole therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00820">Tadalafil</a></td><td>Ketoconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.</td></tr><tr><td><a href="/drugs/DB00675">Tamoxifen</a></td><td>Ketoconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Ketoconazole may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00706">Tamsulosin</a></td><td>Ketoconazole, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Ketoconzole is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB05521">Telaprevir</a></td><td>Strong CYP3A4 inhibitors increase exposure of telaprevir. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Ketoconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.</td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Ketoconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00444">Teniposide</a></td><td>The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>The strong CYP1A2 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Thiothixene, a CYP1A2 substrate. Consider alternate therapy or monitor for changes in Thiothixene therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00906">Tiagabine</a></td><td>The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir may increase the serum concentration of Ketoconazole. </td></tr><tr><td><a href="/drugs/DB00697">Tizanidine</a></td><td>Ketoconazole may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01036">Tolterodine</a></td><td>Ketoconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.</td></tr><tr><td><a href="/drugs/DB06212">Tolvaptan</a></td><td>Ketoconazole is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan by 82%. </td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>The p-glycoprotein inhibitor, Ketoconazole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00214">Torasemide</a></td><td>Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Ketoconazole is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Ketoconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Ketoconazole may decrease the effect of Tramadol by decreasing active metabolite production. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inhibitor, Ketoconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00897">Triazolam</a></td><td>Ketoconazole may increase the effect of the benzodiazepine, triazolam.</td></tr><tr><td><a href="/drugs/DB00440">Trimethoprim</a></td><td>The strong CYP2C9 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>The strong CYP3A4 inhibitor, Ketoconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Ketoconazole is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB08867">Ulipristal</a></td><td>Concomitant therapy with strong CYP3A4 inhibitors may increase plasma concentrations of ulipristal. Avoid combination therapy. </td></tr><tr><td><a href="/drugs/DB00580">Valdecoxib</a></td><td>Ketoconazole may increase the effect and toxicity of valdecoxib.</td></tr><tr><td><a href="/drugs/DB00862">Vardenafil</a></td><td>Ketoconazole, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB08881">Vemurafenib</a></td><td>Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Ketoconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Ketoconazole is initiated, discontinued, or dose changed.</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB06684">Vilazodone</a></td><td>CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone. imit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors. </td></tr><tr><td><a href="/drugs/DB00570">Vinblastine</a></td><td>Ketoconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00541">Vincristine</a></td><td>Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00361">Vinorelbine</a></td><td>Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if ketoconazole is initiated, discontinued or dose changed.	</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00549">Zafirlukast</a></td><td>Ketoconazole, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of zafirlukast. Consider alternate therapy or monitor for changes in zafirlukast therapeutic and adverse effects if ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Ketoconazole increases the effect and toxicity of ziprasidone</td></tr><tr><td><a href="/drugs/DB00425">Zolpidem</a></td><td>Ketoconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if ketoconazole is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00909">Zonisamide</a></td><td>Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if ketoconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01198">Zopiclone</a></td><td>Ketonconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if ketoconazole is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.</li>
<li>Take with food.</li></ul></td></tr></tbody></table>